Tag: date

Director/PDMR Shareholding

The Magnum Ice Cream Company N.V.

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2

T1 Energy to Enter BESS and Data Center Infrastructure Markets with Acquisition of KORE Power

T1 Energy Inc. announced this morning it has entered into a definitive agreement to acquire KORE Power, Inc.

Admission of Further Securities to Trading

OCTOPUS TITAN VCT PLC

FLEURY MICHON : Déclaration mensuelle des droits de vote 05 2026

Société FLEURY MICHON

Zhihu Inc. Reports Unaudited First Quarter 2026 Financial Results

BEIJING, China, June 03, 2026 (GLOBE NEWSWIRE) -- Zhihu Inc. (“Zhihu” or the “Company”) (NYSE: ZH; HKEX: 2390), a leading online content community in China, today announced its unaudited financial results for the quarter ended March 31, 2026.

Transaction in Own Shares

Transaction in Own Shares

MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting

GENEVA, June 3, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics,...

Regulatory release no. 1 – 2026: Publication of Offering Circular and offer price for the Initial Public Offering and admission of the shares of...

3 June 2026

Update of share buy-back programme ForFarmers

Lochem, 3 June 2026

SATO Oyj – Managers’ Transactions

SATO Corporation, Stock Exchange Release 3 June 2026 at 8:15 am

SATO Oyj - Managers' Transactions

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated...

TETRA Technologies, Inc. Announces Pricing of Public Offering of Common Stock

SPRING, Texas, June 2, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) today announced the pricing of an underwritten public...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsDate

NYSE Content Update: Intercontinental Exchange Joins Anthropic’s Project Glasswing

Mercedes-Benz of Westwood Celebrates Grand Opening of Newly Renovated Luxury Dealership

Star Living Introduces Integrated ‘One-Stop Home & Living’ Concept to Simplify Renovation and Furnishing for Singapore Homeowners